A novel advanced glycation index and its association with diabetes and microangiopathy

Metabolism: Clinical and Experimental

Volumn 54, Issue 8, 2005, Pages 1002-1007

  Sampathkumar, Rangasamy ^a   Balasubramanyam, Muthuswamy ^a   Rema, Mohan ^a   Premanand, Chinnaraj ^a   Mohan, Viswanathan ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BUFFER; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIPID; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; FLUORESCENCE; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; CHEMISTRY, CLINICAL; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 22744453679     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2005.02.017     Document Type: Article

References (43)

1. J.W. Baynes, and S.R. Thorpe Role of oxidative stress in diabetic complications: a new perspective on an old paradigm Diabetes 48 1999 1 9
2. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
3. D. Stern, S.D. Yan, S.F. Yan, and A.M. Schmidt Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings Adv Drug Deliv Rev 54 2002 1615 1625
4. R. Bucala, and A. Cerami Advanced glycosylation: chemistry, biology, and implications for diabetes and aging Adv Pharmacol 23 1992 1 34
5. S.F. Yan, R. Ramasamy, Y. Naka, and A.M. Schmidt Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond Circ Res 93 2003 1159 1169
6. N. Ahmed, and P.J. Thornalley Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring Biochem Soc Trans 31 2003 1417 1422
7. M. Deepa, R. Pradeepa, and M. Rema The Chennai Urban Rural Epidemiology Study (CURES)-study design and methodology (urban component) (CURES-I) J Assoc Physicians India 51 2003 863 870
8. M. Rema, V. Mohan, R. Deepa, and R. Ravikumar Association of carotid intima-media thickness and arterial stiffness with diabetic retinopathy: the Chennai Urban Rural Epidemiology Study (CURES-2) Diabetes Care 27 2004 1962 1967
9. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
10. D.W. Cockroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
11. G. Manjunath, M.J. Sarnak, and A.S. Levey Estimating the glomerular filtration rate. Dos and don'ts for assessing kidney function Postgrad Med 110 2001 55 62
12. V. Mohan, R. Meera, G. Premalatha, R. Deepa, P. Miranda, and M. Rema Frequency of proteinuria in type 2 diabetes mellitus seen at a diabetes centre in southern India Postgrad Med J 76 2000 569 573
13. V.M. Monnier, and A. Cerami Nonenzymatic browning in vivo: possible process for aging of long-lived proteins Science 211 1981 491 493
14. G. Munch, R. Keis, and A. Wessels Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA Eur J Clin Chem Clin Biochem 35 1997 669 677
15. S.B. Schwedler, T. Metzger, R. Schinzel, and C. Wanner Advanced glycation end products and mortality in hemodialysis patients Kidney Int 62 2002 301 310
16. K. Yanagisawa, Z. Makita, and K. Shiroshita Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients Metabolism 47 1998 1348 1353
17. A.M. Buongiorno, E. Sagratella, and S. Morelli Two polyclonal antisera detect different AGE epitopes in human plasma samples Immunol Lett 85 2003 243 249
18. J. Miura, S. Yamagishi, and Y. Uchigata Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes J Diabetes Complications 17 2003 16 21
19. A. Galler, G. Muller, and R. Schinzel Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and N epsilon-(carboxymethyl) lysine ELISA Diabetes Care 26 2003 2609 2615
20. M. Takeuchi, Z. Makita, K. Yanagisawa, Y. Kameda, and T. Koike Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients Mol Med 5 1999 393 405
21. Y. Ono, S. Aoki, and K. Ohnishi Increased serum levels of advanced glycation end-products and diabetic complications Diabetes Res Clin Pract 41 1998 131 137
22. H.P. Hammes, M. Brownlee, J. Lin, E. Schleicher, and R.G. Bretzel Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product N epsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations Diabetologia 42 1999 603 607
23. Y. Aso, T. Inukai, K. Tayama, and Y. Takemura Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes Acta Diabetol 37 2000 82 87
24. P.S. Sharp, S. Rainbow, and S. Mukherjee Serum levels of low molecular weight advanced glycation end products in diabetic subjects Diabet Med 20 2003 575 579
25. T. Miyata, M.X. Fu, and K. Kurokawa Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 54 1998 1290 1295
26. R.D.G. Leslie, H. Beyan, and P. Sawtell Levels of an advanced glycated end product is genetically determined: a study of normal twins Diabetes 52 2003 2441 2444
27. J.W. Baynes, and S.R. Thorpe Glycoxidation and lipoxidation in atherogenesis Free Radic Biol Med 28 2000 1708 1716
28. M. Balasubramanyam, M. Rema, and C. Premanand Biochemical and molecular mechanisms of diabetic retinopathy Curr Sci 83 2002 1506 1514
29. T. Gardiner, H. Anderson, and A.W. Stitt Inhibition of advanced glycation end products against retinal capillary basement membrane expansion during long-term diabetes J Pathol 201 2003 328 333
30. N. Nakamura, G. Hasegawa, and H. Obayashi Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy Diabetes Res Clin Pract 61 2003 93 101
31. S. Yamagishi, C.C. Hsu, and M. Taniguchi Receptor-mediated toxicity to pericytes of advanced glycosylation end products. A possible mechanism of pericyte loss in diabetic microangiopathy Biochem Biophys Res Commun 213 1995 681 687
32. P.J. Beisswenger, L.L. Morre, T. Brinck-Johnsen, and T.J. Curphey Increased collagen-linked pentosidine levels and AGEs in early diabetic nephropathy J Clin Invest 92 1993 212 217
33. E. Sato, F. Mori, S. Igarashi, T. Abiko, M. Takeda, and S. Ishiko Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy Diabetes Care 24 2001 479 482
34. S. Sugiyama, T. Miyata, and Y. Ueda Plasma levels of pentosidine in diabetic patients: an advanced glycation end product J Am Soc Nephrol 9 1998 1681 1688
35. Z. Wagner, I. Wittmann, and I. Mazak N(epsilon)-carboxymethyl lysine levels in patients with type 2 diabetes: role of renal function Am J Kidney Dis 38 2001 785 791
36. R. Schiel, S. Franke, and T. Appel Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus-results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN) Eur J Med Res 9 2004 391 399
37. T. Miyata, Y. Ueda, and Y. Yamada Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia J Am Soc Nephrol 9 1998 2349 2356
38. K. Miyazaki, R. Nagai, and S. Horiuchi Creatine plays a direct role as a protein modifier in the formation of a novel advanced glycation end product J Biochem (Tokyo) 132 2002 543 550
39. Y.M. Li, M. Steffes, and T. Donnelly Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine Proc Natl Acad Sci U S A 93 1996 3902 3907
40. M.E. Williams Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease Curr Diab Rep 4 2004 441 446
41. K. Fukami, S. Ueda, and S. Yamagishi AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction Kidney Int 66 2004 2137 2147
42. G. Wolf New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology Eur J Clin Invest 34 2004 785 796
43. J. Malone, O. Bautista, and S. Genuth Advanced glycation end products (AGEs) predict worsening of diabetic retinopathy in Diabetes Control and Complications Trial/Epidemiology of diabetes Interventions and complications (DCCT/EDIC) participants Diabetologia 46 Suppl 2 2003 A42